Cancer drug doses put to the test in healthy volunteers
NCT ID NCT05391048
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested two different strengths (10 mg and 20 mg) of an experimental drug called IMP4297 in 36 healthy Chinese men. The goal was to see if the two strengths are processed the same way in the body after a meal. This is a bioequivalence study, meaning it checks if different doses give the same drug levels in the blood. The results will help decide which strength to use in future studies for solid tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IMP4297 (a drug being tested for solid tumors)
What this could lead to
If successful, this study could confirm that both capsule strengths deliver the same amount of drug, supporting future trials for solid tumor treatment.
What could go wrong
This is a very early, small study in healthy people, not patients. It only checks how the drug is processed, not if it works against cancer. Results may not predict effectiveness or safety in patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Xuzhou Central Hospital
Xuzhou, Jiangsu, 221000, China